NDA 020450 · Parke Davis
Cerebyx
Fosphenytoin Sodium · Injection
NovelLast checked: Nov 20, 2026Latest source record: Apr 28, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1996
Aug 5, 1996
Approved uses
2
Original approval plus efficacy supplements
Registered trials
14
4 Phase 3, 1 recruiting
FAERS reports
1,017
884 serious, 164 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: CARDIOVASCULAR RISK ASSOCIATED WITH RAPID INFUSION RATES The rate of intravenous CEREBYX administration should not exceed 150 mg phenytoin sodium equivalents (PE) per minute in adults and 2 mg PE/kg/min (or 150 mg PE/min, whichever is slower) in pediatric patients because of the risk of severe hypotension and cardiac arrhythmias. Careful cardiac monitoring is needed during and after administering intravenous CEREBYX. Although the risk of cardiovascular toxicity increases with infusion rates above the recommended infusion rate, these events have also been reported at or below the recommended infusion rate. Reduction in rate of administration or discontinuation of dosing may be needed [see Dosage and Administration (2.3 , 2.4) and Warnings and Precautions (5.2) ]. WARNING: CARDIOVASCULAR RISK ASSOCIATED WITH RAPID INFUSION RATES See full prescribing information for complete boxed...
What it is approved for
From the label in effect Aug 28, 2025.
CEREBYX is indicated for the treatment of generalized tonic-clonic status epilepticus and prevention and treatment of seizures occurring during neurosurgery. CEREBYX can also be substituted, short-term, for oral phenytoin. CEREBYX should be used only when oral phenytoin administration is not possible [see Dosage and Administration (2.4) and Warnings and Precautions (5.2) ] . CEREBYX is indicated for the treatment of generalized tonic-clonic status epilepticus and prevention and treatment of seizures occurring during neurosurgery. CEREBYX can also be substituted, as short-term use, for oral phenytoin. CEREBYX should be used only when oral phenytoin administration is not possible. ( 1 )
Mechanism: Fosphenytoin is a prodrug of phenytoin and accordingly, its anticonvulsant effects are attributable to phenytoin. The precise mechanism by which phenytoin exerts its therapeutic effect has not been established but is thought to involve the voltage-dependent blockade of membrane sodium channels resulting in a reduction in sustained high-frequency neuronal discharges.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 1, 2017 Supplement 3 · Efficacy LabelLetterPediatric Medical Review
- Aug 5, 1996 Original approval · Type 1 - New Molecular Entity Review
1 products under this application
- CEREBYX · FOSPHENYTOIN SODIUM EQ 50MG PHENYTOIN NA/ML · INJECTABLE, INJECTION · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Fosphenytoin" as an intervention, any sponsor and status, largest first.
- Established Status Epilepticus Treatment TrialPivotal-lookingCompleted
University of VirginiaAcademic, hospital or other
NCT01960075 · 478 participants · Start Oct 2015 · Primary completion Feb 2019
Drug: Fosphenytoin; Levetiracetam and 1 more · For: Benzodiazepine Refractory Status Epilepticus
Sites: Tucson, Arizona; Los Angeles, California; Sacramento, California · 65 sites in all
- Comparison Between Lorazepam, Clonazepam and Clonazepam + Fosphenytoin for the Treatment of Out-of-hospital Generalized Status EpilepticusPivotal-lookingCompleted
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
NCT01870024 · 434 participants · Start Jun 26, 2013 · Primary completion Feb 23, 2018
Drug: Clonazepam; Fosphenytoin and 2 more · For: Status Epilepticus; Epilepsy
Sites: Paris, France
Center for International Blood and Marrow Transplant ResearchResearch network
NCT06859424 · 358 participants (planned) · Start Jul 25, 2025 · Primary completion Jun 2028
Drug: Conditioning Regimen A; Conditioning Regimen B and 12 more · For: AML (Acute Myelogenous Leukemia); Acute Lymphoid Leukemia (ALL); Acute Leukemia (Category) and 8 more
Sites: Birmingham, Alabama; Duarte, California; Palo Alto, California · 13 sites in all
- IV Keppra in the Emergency Department for Prevention of Early Recurrent SeizuresPivotal-lookingCompleted
Emory UniversityAcademic, hospital or other
NCT00510783 · 158 participants · Start Jul 2007 · Primary completion Dec 2008
Drug: Keppra; Fosphenytoin and 1 more · For: Tonic-clonic Seizure
Sites: Atlanta, Georgia
Aatif HusainAcademic, hospital or other
NCT01458522 · 74 participants · Start May 2012 · Primary completion Jul 2014
Drug: fPHT; LCM · For: Nonconvulsive Seizures
Sites: Pasadena, California; New Haven, Connecticut; Atlanta, Georgia · 11 sites in all
- The Efficacy and Safety of Levetiracetam Versus Fosphenytoin in Convulsive Status EpilepticusCompleted
Dhaka Medical CollegeAcademic, hospital or other
NCT06403150 · 62 participants · Start May 15, 2023 · Primary completion Aug 31, 2024
Drug: Levetiracetam Injection; Fosphenytoin Injection · For: Status Epilepticus
Sites: Dhaka, Bangladesh
Thomas Jefferson UniversityAcademic, hospital or other
NCT00774306 · 52 participants · Start Apr 2009 · Primary completion Jun 2012
Drug: phenytoin; valproate and 1 more · For: Subarachnoid Hemorrhage
University of CincinnatiAcademic, hospital or other
NCT00618436 · 52 participants · Start Aug 2007 · Primary completion Sep 2009
Drug: Levetiracetam; Phenytoin · For: Traumatic Brain Injury; Subarachnoid Hemorrhage
Sites: Cincinnati, Ohio
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective127
- off label use70
- hypotension50
- status epilepticus49
- cardiac arrest48
- seizure44
- convulsion41
- pyrexia41
- stevens-johnson syndrome34
- blood pressure decreased30
- toxicity to various agents29
- drug interaction26
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 36 |
| 2005 | 33 |
| 2006 | 50 |
| 2007 | 28 |
| 2008 | 28 |
| 2009 | 13 |
| 2010 | 20 |
| 2011 | 22 |
| 2012 | 54 |
| 2013 | 71 |
| 2014 | 72 |
| 2015 | 68 |
| 2016 | 68 |
| 2017 | 89 |
| 2018 | 41 |
| 2019 | 16 |
| 2020 | 39 |
| 2021 | 33 |
| 2022 | 68 |
| 2023 | 59 |
| 2024 | 47 |
| 2025 | 37 |
| 2026 | 25 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Cerebyx (Fosphenytoin Sodium)
2024 spending
$45K
Beneficiaries
n/a
66 claims
Per beneficiary
n/a
$12.40 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $27,501 |
| 2021 | $61,548 |
| 2022 | $79,278 |
| 2023 | $50,837 |
| 2024 | $44,900 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus.
Kapur J, Elm J, Chamberlain JM, et al. · N Engl J Med 2019 · Comparative Study, Multicenter Study
- Guidelines for Seizure Prophylaxis in Adults Hospitalized with Moderate-Severe Traumatic Brain Injury: A Clinical Practice Guideline for Health Care Professionals from the Neurocritical Care Society.
Frontera JA, Gilmore EJ, Johnson EL, et al. · Neurocrit Care 2024 · Systematic Review, Practice Guideline
- Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT): a double-blind, responsive-adaptive, randomised controlled trial.
Chamberlain JM, Kapur J, Shinnar S, et al. · Lancet 2020 · Multicenter Study, Randomized Controlled Trial
- Guidelines for Seizure Prophylaxis in Patients Hospitalized with Nontraumatic Intracerebral Hemorrhage: A Clinical Practice Guideline for Health Care Professionals from the Neurocritical Care Society.
Frontera JA, Rayi A, Tesoro E, et al. · Neurocrit Care 2025 · Systematic Review, Practice Guideline
- Treatment of benzodiazepine-resistant status epilepticus: Systematic review and network meta-analyses.
Jain P, Aneja S, Cunningham J, et al. · Seizure 2022 · Systematic Review, Network Meta-Analysis
- Prospective, randomized, single-blinded comparative trial of intravenous levetiracetam versus phenytoin for seizure prophylaxis.
Szaflarski JP, Sangha KS, Lindsell CJ, et al. · Neurocrit Care 2010 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.